This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Bevacizumab
From Proteopedia
|
Better Known as: Avastin
- Marketed By: Genentech & Roche
- Major Indication: Colorectal Cancer
- Drug Class: Vascular Endothelial Growth Factor Inhibitor - Monoclonal Antibody
- Date of FDA Approval (Patent Expiration): 2004 (2019)
- 2009 Sales: $4.8 Billion
- Importance: It is one of the best selling cancer treatments in history. Despite being effective against colorectal cancer, post-approval studies after accelerated approval revealed that Avastin was ineffective in treating breast cancer. Many question the $90,000/year bill to take Avastin when it extends life on average only 10 months.
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| VEGF Inhibitor Pharmacokinetics[1] | |
|---|---|
| Parameter | Bevacizumab |
| Tmax (hr) | 5.17 |
| Cmax (ng/ml) | 284000 |
| Bioavailability (%) | 100 |
| T1/2 (days) | 20 |
| AUC (ug/ml/hr) | 97488 |
| IC50 (nM) | .9 |
| Clearance (L/h) | .0096 |
| Dosage (mg/kg) | 10 |
References
- ↑ Garnier-Viougeat N, Rixe O, Paintaud G, Ternant D, Degenne D, Mouawad R, Deray G, Izzedine H. Pharmacokinetics of bevacizumab in haemodialysis. Nephrol Dial Transplant. 2007 Mar;22(3):975. Epub 2006 Nov 8. PMID:17093010 doi:10.1093/ndt/gfl664
Proteopedia Page Contributors and Editors (what is this?)
David Canner, Michal Harel, Joel L. Sussman, Alexander Berchansky
